Clinical and radiologic features of encephalopathy during 2011 e coli O111 outbreak in Japan

Neurology

Volumn 82, Issue 7, 2014, Pages 564-572

  Takanashi, Jun Ichi ^a   Taneichi, Hiromichi ^b   Misaki, Takako ^c   Yahata, Yuichiro ^c   Okumura, Akihisa ^d   Ishida, Yoh Ichi ^e   Miyawaki, Toshio ^b   Okabe, Nobuhiko ^c   Sata, Tetsutaro ^f   Mizuguchi, Masashi ^g  

^a KAMEDA MEDICAL CENTER   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TOYAMA CITY HOSPITAL   (Japan)

^f TOYAMA INSTITUTE OF HEALTH   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; METHYLPREDNISOLONE;

ADOLESCENT; ADULT; ARTICLE; BRAIN EDEMA; BRAIN INFECTION; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DRUG PULSE THERAPY; EPIDEMIC; ESCHERICHIA COLI INFECTION; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; JAPAN; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MORTALITY; NEUROIMAGING; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SHIGA TOXIN PRODUCING ESCHERICHIA COLI O111; SHIGA TOXIN PRODUCING ESCHERICHIA COLI O111 ENCEPHALOPATHY; YOUNG ADULT;

ADULT; CHILD; DISEASE OUTBREAKS; ESCHERICHIA COLI INFECTIONS; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; JAPAN; MALE; METHYLPREDNISOLONE; NEUROTOXICITY SYNDROMES; PULSE THERAPY, DRUG; RETROSPECTIVE STUDIES; SHIGA-TOXIGENIC ESCHERICHIA COLI; TREATMENT OUTCOME;

EID: 84895772430     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000120     Document Type: Article

References (40)

1. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005;365:1073-1086.
2. Pennington H. Escherichia coli O157. Lancet 2010;376: 1428-1435.
3. Nathanson S, Kwon T, Elmaleh M, et al. Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2010;5:1218-1228.
4. Donnerstag F, Ding X, Pape L, et al. Patterns in early diffusion-weighted MRI in children with haemolytic uremic syndrome and CNS involvement. Eur Radiol 2012; 22:506-513.
5. Piercefield EW, Bradley KK, Coffman RL, Mallonee SM. Hemolytic uremic syndrome after an Escherichia coli O111 outbreak. Arch Intern Med 2010;170:1656-1663.
6. Weissenborn K, Donnerstag F, Kielstein JT, et al. Neurologic manifestations of E coli infection-induced hemolyticuremic syndrome in adults. Neurology 2012;79:1466-1473.
7. Magnus T, Röther J, Simova O, et al. The neurological syndrome in adults during the 2011 northern German E. coli serotype O104:H4 outbreak. Brain 2012;135:1850-1859.
8. Shimizu M, Kuroda M, Sakashita N, et al. Cytokine profiles of patients with enterohemorrhagic Escherichia coli O111-induced hemolytic-uremic syndrome. Cytokine 2012;60:694-700.
9. The Research Committee on the Clarification of the Etiology and on the Establishment of Therapeutic and Preventive Measures for Influenza Encephalopathy. Guidelines for Influenza Encephalopathy. Japan:Ministry of Health, Labor and Welfare; 2009:23-32.
10. Matano S, Inamura K, Konishi M, et al. Encephalopathy, disseminated intravascular coagulation, and hemolytic-uremic syndrome after infection with enterohemorrhagic Escherichia coli O111. J Infect Chemother 2012;18:558-564.
11. Gould LH, Demma L, Jones TF, et al. Hemolytic uremic syndrome and death in persons with Escherichia coli O157:H7 infection, Foodborne Diseases Active Surveillance Network sites, 2000-2006. Clin Infect Dis 2009; 49:1480-1485.
12. Loos S, Ahlenstiel T, Kranz B, et al. An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis 2012; 55:753-759.
13. Frank C, Werber D, Cramer JP, et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Eng J Med 2011;365:1171-1180.
14. Obata F, Tohyama K, Bonev AD, et al. Shiga toxin 2 affects the central nervous system through receptor globotriaosylceramide localized to neurons. J Infect Dis 2008; 198:1398-1406.
15. Jones NL, Islur A, Haq R, et al. Escherichia coli Shiga toxins induce apoptosis in epithelial cells that is regulated by the bcl-2 family. Am J Physiol Gastrointest Liver Physiol 2000;278:G811-G819.
16. Erwert RD, Eiting KT, Tupper JC, Winn RK, Harlan JM, Bannerman DD. Shiga toxin induces decreased expression of the antiapoptotic protein Mcl-1 concomitant with the onset of endothelial apoptosis. Microb Pathog 2003;35:87-93.
17. Fujii J, Kinoshita Y, Kita T, et al. Magnetic resonance imaging and histopathological study of brain lesions in rabbits given intravenous verotoxin. Infect Immun 1996;64: 5053-5060
18. Takahashi K, Funata N, Ikuta F, Sato S. Neuronal apoptosis and inflammatory responses in the central nervous system of a rabbit treated with Shiga toxin-2. J Neuroinflammation 2008;5:11.
19. Goldstein J, Loidl CF, Creydt VP, Boccoli J, Ibarra C. Intracerebroventricular administration of Shiga toxin type 2 induces striatal neuronal death and glial alterations: an ultrastructural study. Brain Res 2007;1161:106-115.
20. Tironi-Farinati C, Loidl CF, Boccoli J, Parma Y, Fernandez-Miyakawa ME, Goldstein J. Intracerebroventricular Shiga toxin 2 increases the expression of its receptor globotriaosylceramide and causes dendritic abnormalities. J Neuroimmun 2010;222:48-61.
21. Ramegowda B, Samuel JE, Tesh VL. Interaction of Shiga toxins with human brain microvascular endothelial cells: cytokines as sensitizing agents. J Infect Dis 1999;180: 1205-1213.
22. Eisenhauer PB, Chaturvedi P, Fine RE, et al. Tumor necrosis factor alpha increases human cerebral endothelial cell Gb3 and sensitivity to Shiga toxin. Infect Immun 2001;69:1889-1894.
23. Stricklett PK, Hughes AK, Ergonul Z, Kohan DE. Molecular basis for up-regulation by inflammatory cytokines of Shiga toxin 1 cytotoxicity and globotriaosylceramide expression. J Infect Dis 2002;186:976-982
24. Aloisi F. Immune function of microglia. Glia 2001;36: 165-179.
25. Yang L, Lindholm K, Konishi Y, Li R, Shen Y. Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways. J Neurosci 2002;22: 3025-3032.
26. Akassoglou K, Bauer J, Kassiotis G, et al. Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am J Pathol 1998; 153:801-813.
27. Zhao X, Bausano B, Pike BR, et al. TNF-a stimulates caspase-3 activation and apoptotic cell death in primary septo-hippocampal cultures. J Neurosci Res 2001;64: 121-131.
28. Nishida N, Hata Y, Sasahara M, Ishii Y, Hamashima T, Shin J. Postmortem examination in patients with O111 infection [in Japanese]. Sata T, editor. Annual Report on Epidemiology, Microbiologic Features and Clinical Manifestations in EHEC/O111 Outbreak. Special Research (H23-TOKUBETU-SHITEI-004) . Japan: Ministry of Health, Labor and Welfare of Japan; 2012:179-182.
29. Mizuguchi M, Yamanouchi H, Ichiyama T, Shiomi M. Acute encephalopathy associated with influenza and other viral infections. Acta Neurol Scand 2007;115:45-56.
30. Takanashi J. Two newly proposed encephalitis/encephalopathy syndromes. Brain Dev 2009;31:521-528.
31. Ichiyama T, Isumi H, Ozawa H, Matsubara T, Moroshima T, Furukawa S. Cerebrospinal fluid and serum levels of cytokines and soluble tumor necrosis factor receptor in influenza virus-associated encephalopathy. Scand J Infect Dis 2003;35:59-61.
32. Ichiyama T, Endo S, Kaneko M, Ishumi H, Matsubara T, Furukawa S. Serum cytokine concentrations of influenzaassociated acute necrotizing encephalopathy. Pediatr Int 2003;45:734-736.
33. Flammer JR, Rogatsky I. Glucocorticoids in autoimmunity: unexpected targets and mechanisms. Mol Endocrinol 2011;25:1075-1086.
34. Okumura A, Mizuguchi M, Kidokoro H, et al. Outcome of acute necrotizing encephalopathy in relation to treatment with corticosteroids and gammaglobulin. Brain Dev 2009;31:221-227.
35. Takanashi J, Oba H, Barkovich AJ, et al. Diffusion MRI abnormalities after prolonged febrile seizures with encephalopathy. Neurology 2006;66:1304-1309.
36. Shinohara M, Saitoh M, Takanashi JI, et al. Carnitine palmitoyl transferase II polymorphism is associated with multiple syndromes of acute encephalopathy with various infectious diseases. Brain Dev 2011;33:512-517.
37. Shinohara M, Saitoh M, Nishizawa D, et al. ADOR2A polymorphism predisposes children to encephalopathy with febrile status epilepticus. Neurology 2013;80:1-6.
38. Watahiki M, Ohnishi M, Sekizuka T. Summary of microbiologic research (in Japanese). Sata T, editor. Annual Report on Epidemiology, Microbiologic Features and Clinical Manifestations in EHEC/O111 Outbreak. Special Research (H23-TOKUBETU-SHITEI-004). Japan: Ministry of Health, Labor and Welfare of Japan; 2012;99-103.
39. Siegler RL. Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome. J Pediatr 1994;125: 511-518.
40. Ahrens F, Ludwig K, Terstegge K, Querfeld U. Encephalopathy and exposure to Shiga toxin without evidence of haemolytic uraemic syndrome. Eur J Pediatr 2002;16: 462-463.